|
Study | Country | Modelling approach | Time horizon | Discounting (C/B) | Perspective | Sensitivity analysis | Population |
|
Kabeshova et al., [15] | France | Markov model | 2 years and 5 years | NR | French national health insurance | 1-way and PSA | years and in remission from previous episodes of OHE, associated with hepatic cirrhosis (equivalent to conn ) |
Bajaj et al., [22] | United States | Markov model | 5 years | 3.0% | Societal perspective | Univariate | A simulated cohort of 1000 cirrhotic patients with compensated liver disease and without OHE, from entry into treatment |
Congly et al., [25] | United States | Markov model | 5 years | NR | Third-party payer’s perspective | 1 way | Patients in remission from previous OHE |
Jesudian et al., [14] | United States | Markov model | Lifetime | 3.0% | Third-party US payer perspective | Univariate, PSA | Patients in remission of recurrent HE |
Huang et al., [26] | United States | Markov model | Lifetime | 3.0% | Third-party US payer perspective | 1 way | Patients entered the model without previous treatment for HE and were then allocated among 6 treatment strategies |
Rivas et al., [31] | Mexico | Decision tree model | 14 days | 5.0% | Mexican Institute of Social Security perspective | Univariate | Patients with acute HE |
Berni et al., [13] | United Kingdom | Markov model | 2 years, 5 years, 10 years, and lifetime | 3.5% | UK National Health Service | Deterministic and PSA | Adult cirrhotic patients in remission (conn score 0-1) from recurrent OHE episodes (≥ 2 prior episodes) |
Cardona et al., [24] | Mexico | Decision tree model | 10 days | NR | Mexican Institute of Social Security (IMSS) perspective | Univariate | Patients with HE |
Whitehouse et al., [32] | Netherlands | Markov model | 5 years | 4.0%/1.5% | NR | NR | Patients with liver cirrhosis |
Paul et al., [28] | NR | Markov model | 6 months, 1 year, and lifetime | NR | Third-party payer’s perspective | Unspecified | Adult patients ( years) with OHE |
Poole et al., [30] | United Kingdom | Markov model | 5 years and 10 years | 3.5%/3.5% | UK National Health Service payer perspective | Unspecified | Cirrhotic patients with OHE |
Poole et al., [29] | Sweden | Markov model | 5 years, 10 years, and lifetime | 3.5%/3.5% | Payer perspective of the Swedish healthcare system | Unspecified | Cirrhotic patients with OHE |
Berni et al., [23] | Belgium | Markov model | 5 years, 10 years, and lifetime | 3.5%/1.5% | Payer perspective of the Belgian healthcare system | NR | Cirrhotic patients with recurrent OHE |
Alhawwashi et al., [21] | Saudi Arabia | NR | NR | NR | Healthcare payer perspective: Tertiary hospital in Riyadh, Saudi Arabia | NR | Patients with HE |
Koh et al., [27] | Singapore | Markov model | NR | NR | NR | NR | Patients with HE |
|